|
KMID : 0378019880310110113
|
|
New Medical Journal
1988 Volume.31 No. 11 p.113 ~ p.118
|
|
|
The Safety and Therapeutic Efficacy of Human Leukocyte Interferon in patients with Chronic Active Hepatitis type B
|
|
|
|
|
Abstract
|
|
|
This study aimed to evaluate the effect of human leukocvte interferon on hepatitis B virus in patients with chronic active hepatitis type B. Human leukocyte interferon (HLI) was parenterally administer; d to 30 patients (male 25, female 5) who were found to have elevated transaminase activities, persistently positive HBsAg and HBeAg, and high and high level of DNA polymerase activitiy. The therapeutic dose of LI was daily 3 x 106 IU given subcutanously, 3 times a week for 12 weeks and total dosage of HLI was 108 106 IU.
The following results were obtained.
1. In eleven of 30 patients who had received HLI, DNA polymerase activities were decreased to nor al state just after 12 weeks administration.
2. 11 patients became seronegative and 10 patients of them became seroconversion (Anti-HBs) during and after the administration period.
3. In all patients, the significant decrease of peripheral white blood cell, granulocyte and platelet counts is were observed during the HLI treatment but recovered as the pretreatment state within 2 weeks of after discontinuation of HLI.
4. Side effects of HLI including myalgia and fever (93%), mild anorexia (33.3%) and hair loss (0.7%) we e noted.
From these results, we concluded that HLI therapy, if given in a subcutaneous injection of 3 x 101 I daily, 3 times a week for 12 weeks is beneficial to patients with HBsAg and HBeAg positive chronic active hepatitis type B.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|